Corcept Therapeutics Incorporated (CORT) — Capital Reinvestment Ratio

Latest as of December 2025: 0.00x

Corcept Therapeutics Incorporated (CORT) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow ($38.45 Million) in capital expenditures ($50.00K). Check Corcept Therapeutics Incorporated (CORT) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$38.45 Million
USD

Capital Expenditures

$50.00K
USD

Data as of

Dec 2025
Most recent filing

Corcept Therapeutics Incorporated Capital Reinvestment Ratio (2015–2025)

This chart tracks Corcept Therapeutics Incorporated's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Corcept Therapeutics Incorporated.

Annual Capital Reinvestment Ratio for Corcept Therapeutics Incorporated (2015–2025)

Year-by-year Capital Reinvestment Ratio for Corcept Therapeutics Incorporated from 2015 to 2025. See CORT free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.00x $142.00 Million $211.00K ▼ -86.4%
2024 0.01x $198.07 Million $2.17 Million ▲ +902.2%
2023 0.00x $127.04 Million $139.00K ▼ -68.1%
2022 0.00x $120.32 Million $413.00K ▲ +22.9%
2021 0.00x $167.89 Million $469.00K ▼ -65.7%
2020 0.01x $151.97 Million $1.24 Million ▲ +1.9%
2019 0.01x $136.12 Million $1.09 Million ▲ +210.2%
2018 0.00x $115.67 Million $298.00K ▼ -62.5%
2017 0.01x $60.94 Million $419.00K ▼ -34.8%
2016 0.01x $18.39 Million $194.00K ▲ +94.2%
2015 0.01x $3.13 Million $17.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow